Carole Nicco
Has grant
Chief Scientific Officer
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Dr. Carole Nicco serves as the Chief Scientific Officer at BioSenic, located in Belgium. Her research areas focus on systemic sclerosis, inflammation, and microbial interactions in health and disease, as evidenced by her recent publications on topics such as the impact of diet on endometriotic lesions and therapeutic strategies for autoimmune conditions. Dr. Nicco is actively exploring innovative treatments and mechanisms involved in fibrosis and chronic graft-versus-host disease.
Recent Grants
Grant: Close
Study of redox modulators biological activity in vivo for the treatment of systemic sclerosis
Open Date: 2020-06-01
Close Date: 2022-06-01
Grant: Close
Role of the PD1 / PD-L1 interaction in the proliferation of endometriotic lesions in a mouse model and in humans
Open Date: 2019-06-01
Close Date: 2021-06-01
Grant: Close
Evaluation de l’effet de probiotiques sur le développement de l’endométriose dans un modèle murin
Open Date: 2019-01-01
Close Date: 2021-01-01
Grant: Close
Prevention by Levitiracetam of peripheral neuropathies induced by oxaliplatin
Open Date: 2018-01-01
Close Date: 2019-01-01
Grant: Close
STRESS OXYDANT DANS UN MODELE DE MACROPHAGE ACTIVE PAR LE LPS
Open Date: 2016-01-01
Close Date: 2018-01-01
Articles (11)
Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic skin hardening, which combines Raynaud’s phenomenon and other vascular disorders, skin and internal organ fibrosis, immune disorders, and a variety of other abnormalities. Symptoms vary widely among individuals, and personalized treatment is sought for each patient. Since there is no fundamental cure for SSc, it is designated as an intractable disease with patients receiving government subsidies for medical expenses in Japan. Oxidative stress (OS) has been reported to play an important role in the cause and symptoms of SSc. HOCl-induced SSc mouse models are known to exhibit skin and visceral fibrosis, vascular damage, and autoimmune-like symptoms observed in human SSc. The antioxidant combination Twendee X® (TwX) is a dietary supplement consisting of vitamins, amino acids, and CoQ10. TwX has been proven to prevent dementia in humans with mild cognitive impairment and significantly improve cognitive impairment in an Alzheimer’s disease mouse model by regulating OS through a strong antioxidant capacity that cannot be achieved with a single antioxidant ingredient. We evaluated the effectiveness of TwX on various symptoms of HOCl-induced SSc mice. TwX-treated HOCl-induced SSc mice showed significantly reduced lung and skin fibrosis compared to untreated HOCl-induced SSc mice. TwX also significantly reduced highly oxidized protein products (AOPP) in serum and suppressed Col-1 gene expression and activation of B cells involved in autoimmunity. These findings suggest that TwX has the potential to be a new antioxidant treatment for SSc without side effects.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (5)
Helene Bertrand
Associate Professor
Sorbonne Université
Thierry Tchenio
Université Paris-Saclay
Julie Guillermet-Guibert
Université de Toulouse
Clotilde Policar
Professor
École Normale Supérieure
Haruhiko Inufusa
Gifu University
Make your next move.
Prepare your application
Review drafts before you send them.